Report #2831534

Received Mar 14, 2025

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex: Female
Age: 75 yrs
State: NY
Recovered: Unknown
Vaccinated: Mar 4, 2025
Onset: Mar 4, 2025
Days to onset: 0
Hospital days: —

Vaccines (1)

Type	Name	Manufacturer	Dose	Lot	Route / Site
VARZOS	ZOSTER (SHINGRIX)	GLAXOSMITHKLINE BIOLOGICALS	2	3334y	—

Symptoms (1)

Inappropriate schedule of product administration

Symptom narrative

late second dose; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of drug dose administration interval too long in a 75-year-old female patient who received Herpes zoster (Shingrix) (batch number 3334y, expiry date 25-MAR-2027) for prophylaxis. Previously administered products included Shingrix (Patient received first dose in DEC-2020). On 04-MAR-2025, the patient received the 2nd dose of Shingrix. On 04-MAR-2025, an unknown time after receiving Shingrix, the patient experienced drug dose administration interval too long (Verbatim: late second dose). The outcome of the drug dose administration interval too long was not applicable. Additional Information: GSK Receipt Date: 04-MAR-2025 Pharmacist reported that patient received 1st dose of Shingrix in DEC-2020 and received 2nd dose on 4-MAR-2025. The patient received 2nd dose of Shingrix, later than the recommended interval, which led to lengthening of vaccinations schedule.